A review of the current published spinal literature regarding bone morphogenetic protein-2: An insight into potential bias

Current Reviews in Musculoskeletal Medicine

Volumn 7, Issue 3, 2014, Pages 182-188

  Skovrlj, Branko ^a   Marquez Lara, Alejandro ^b   Guzman, Javier Z ^a   Qureshi, Sheeraz A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

InFUSE; Investigation; Medtronic Inc; Pilot trials; Potential bias; Recombinant human bone morphogenetic protein 2; rhBMP 2; Underreporting of adverse events; YODA

Indexed keywords

COLLAGEN SPONGE; INFUSE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANTERIOR SPINE FUSION; ARACHNOIDITIS; ARTHRODESIS; BLADDER DISEASE; BLOOD VESSEL INJURY; BONE GRAFT; CERVICAL SPINE; CONFLICT OF INTEREST; CONTROL GROUP; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; EDEMA; ENTEROPATHY; FOREIGN BODY REACTION; FRACTURE; FRACTURE NONUNION; GASTROINTESTINAL DISEASE; HEMATOMA; HETEROTOPIC OSSIFICATION; HUMAN; ILIAC CREST; INFECTION; LUMBAR SPINE; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; OSTEOLYSIS; POSTERIOR LUMBAR INTERBODY FUSION; POSTEROLATERAL LUMBAR FUSION; PRIORITY JOURNAL; PSEUDARTHROSIS; RADICULOPATHY; RESPIRATORY TRACT DISEASE; RETROGRADE EJACULATION; RETROPHARYNGEAL EDEMA; RETROPHARYNGEAL SWELLING; REVIEW; SCAR FORMATION; SEROMA; SPINAL CORD DISEASE; SPINE FUSION; SURGICAL TECHNIQUE; SWELLING; SYSTEMATIC ERROR; TRANSFORAMINAL LUMBAR INTERBODY FUSION; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; WOUND COMPLICATION;

EID: 84906790606     PISSN: 1935973X     EISSN: 19359748     Source Type: Journal    
DOI: 10.1007/s12178-014-9221-3     Document Type: Review

References (48)

1. Abate M, Vanni D, Pantalone A, et al. Cigarette smoking and musculoskeletal disorders. Muscles Ligaments Tendons J. 2013;3:63-9.
2. Grabowski G, Robertson RN. Bone allograft with mesenchymal stem cells: a critical review of the literature. Hard Tissue. 2013;2:20.
3. Arrington ED, Smith WJ, Chambers HG, et al. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res. 1996;326:300-9. (Pubitemid 26274684)
4. Banwart JC, Asher MA, Hassanein RS. Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. Spine. 1995;20:1055-60.
5. Summers BN, Eistein SM. Donor site pain from the ileum: a complication of lumbar spine fusion. J Bone Joint Surg (Br). 1989;71:677-80. (Pubitemid 19211233)
6. Howard JM, Glassman SD, Carreon LY. Posterior iliac crest pain after posterolateral fusion with or without iliac crest graft harvest. Spine J. 2011;11:534-7.
7. Resnick D, Bozic KJ. Meta-analysis of trials of recombinant human bone morphogenetic protein-2: what should spine surgeons and their patients do with this information? Ann Intern Med. 2013;158:912-3.
8. Food and Drug Administration. InFUSE™ Bone Graft/LT-CAGE™ Lumbar Tapered Fusion Device - P000058. Available at: http://www.fda.gov/ MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/ recently-approveddevices/ucm083423.htm. Accessed 26 Jan 2014.
9. Ye L, Mason MD, Jiang WG. Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci. 2011;16:865-97.
10. Blanco Calvo M, Bolós Fernández V, Medina Villaamil V, et al. Biology of BMP signalling and cancer. Clin Transl Oncol. 2009;11:126-37.
11. Even J, Eskander M, Kang J. Bone morphogenetic protein in spine surgery: current and future uses. J Am Acad Orthop Surg. 2012;20:547-52.
12. Zdeblick TA, Ghanayem AJ, Rapoff AJ, et al. Cervical interbody fusion cages. An animal model with and without bone morphogenetic protein. Spine. 1998;23:758-65.
13. Cook SD, Baffes GC, Wolfe MW, et al. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg Am. 1994;76:827-38. (Pubitemid 24213211)
14. Gerhart TN, Kirker-Head CA, Kriz MJ, et al. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop. 1993;293:317-26. (Pubitemid 23242887)
15. Heckman JD, Boyan BD, Aufdemorte TB, et al. The use of bone morphogenetic protein in the treatment of non-union in a canine model. J Bone Joint Surg. 1991;73:750-64.
16. Simmons DJ, Calhoun JH, Zimmerman B, et al. Effect of recombinant human bone morphogenetic protein 2 (rhBMP-2) on the healing of cortical bone in the rabbit tibia. Proc Orthop Res Soc. 1994;40:507.
17. Martin Jr GJ, Boden SD, Marone MA, et al. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a non-human primate: important lessons learned regarding dose, carrier and safety. J Spinal Disord. 1999;12:179-86. (Pubitemid 30263403)
18. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine. 2000;25:376-81. (Pubitemid 30097051)
19. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine. 2002;27:2662-73. (Pubitemid 35425320)
20. Burkus JK, Gomet MF, Dickman CA, Zdeblick TA. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech. 2002;15:337-49.
21. Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine. 2002;27:2396-408. (Pubitemid 35266228)
22. Burkus JK, Heim SE, Gornet MF, Zdeblick TA. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech. 2003;16:113-22.
23. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine. 2003;28:1219-24. discussion 1225.
24. Haid RW, Branch CL, Alexander JT, Burkus JK. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004;4:527-38. discussion 538-9.
25. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural cortical allografts surgery: clinical and radiographic outcomes in anterior lumbar spinal fusion. J Bone Joint Surg Am. 2005;87:1205-12.
26. Boakye M, Mummaneni PV, Garrett M, et al. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine. 2005;2:521-5.
27. Dimar JR, Glassman SD, Burkus KJ, Carreon LY. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix vs iliac crest bone graft. Spine. 2006;31:2534-9. discussion 2540.
28. Glassman SD, Dimar JR, Burkus K, et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine. 2007;32:1693-8. (Pubitemid 47051857)
29. Dimar JR, Glassman SD, Burkus JK, et al. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am. 2009;91:1377-86.
30. Dawson E, Bae HW, Burkus JK, et al. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial. J Bone Joint Surg Am. 2009;91:1604-13.
31. Zara JN, Siu RK, Zhang X, et al. High dose of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng A. 2011;17:1389-99.
32. Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 2009;302:58-66.
33. Ong KL, Villarraga ML, Lau E, et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine. 2010;35:1794-800.
34. Epstein NE. Complications due to the use of BMP/INFUSE in spine surgery: the evidence continues to mount. Surg Neurol Int. 2013;4 Suppl 5:S343-52.
35. U.S. Food and Drug Administration. FDA Public Health Notification: Life-threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. Available at: http://www.fda.gov/medicaldevices/safety/alertsandnotices/ publichealthnotifications/ucm062000.htm. Accessed 26 Jan 2014.
36. U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data. Available at: http://www.accessdata.fda.gov/cdrh-docs/pdf/P000058b.pdf. Accessed 27 Jan 2014.
37. Armstrong D, Burton T. Medtronic says device for spine faces probe. Wall Street J. November 19, 2008. Available at: http://online.wsj.com/news/articles/ SB122706488112540161. Accessed 26 Jan 2014.
38. Abelson R. Whistle-blower suit says device maker generously rewards doctors. NY Times. January 24, 2006. Available at: http://www.nytimes.com/2006/ 01/24/business/24device.html?pagewanted=all. Accessed 26 Jan 2014.
39. Fauber J. Doctors' financial stake in Medtronic product questioned. Milwaukee J Sentinel. September 5, 2010.Available at: http://www.twincities.com/ ci-15995191. Accessed 26 Jan 2014.
40. Fauber J. Doctors question journal articles: Medtronic paid surgeons millions for other products. Milwaukee J Sentinel. December 26, 2010. Available at: http://www.jsonline.com/watchdog/watchdogreports/112487909.html. Accessed 26 Jan 2014.
41. Meier B, Wilson D. Medtronic Bone-Growth Product Scrutinized. NY Times. April 11, 2011. Available at: http://www.nytimes.com/2011/04/12/business/ 12device.html. Accessed 26 Jan 2014.
42. Armstrong D. Medtronic Product Linked to Surgery Problems. Wall Street J. September 4, 2008. Available at: http://online.wsj.com/news/articles/ SB122047307457096289. Accessed 26 Jan 2014.
43. •• Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bonemorphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11:471-91. This study compared the conclusions of the safety and efficacy published in the original rhBMP-2 industry-sponsored trials with the FDA data summaries, follow-up publications, and administrative and organizational databases exposing potential conflicts of interest and biases in the studies designs.
44. Dimitriou R, Matalioakis GI, Angoules AG, et al. Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury. 2011;42 Suppl 2:S3-15.
45. Kmietowicz Z. Senators question Medtronic about unreported side effects of spinal protein. Br Med J. 2011;343:d4284.
46. Laine C, Guallar E, Murlow C, et al. Closing in on the truth about recombinant human bone morphogenetic protein-2: evidence synthesis, data sharing, peer review, and reproducible research. Ann Intern Med. 2013;158:916-8.
47. •• Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med. 2013;158:877-89. This was one of the 2 independent reviews of all published and unpublished data on the safety and effectiveness of rhBMP-2 by the Yale University Open Data Access Project concluding that there was no evidence of significant difference between the effectiveness of rhBMP-2 compared with ICBG.
48. • Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158:890-902. The second of the 2 independent reviews on the safety of rhBMP-2 by the Yale University Open Data Access Project that concluded that early journal publications misinterpreted the effectiveness and adverse events through selective reporting, duplicate publication and underreporting.